ABSTRACT
INTRODUCTION
In the 1990s, Lo et al. described the presence of cell-free DNA (cfDNA) in the maternal circulation and reported that the concentrations of fetal DNA were increased in the plasma of women carrying fetuses with trisomy 21 1, 2 . Screening for chromosomal abnormalities based on cell-free fetal DNA has become clinically available since 2011 given its high accuracy for the detection of trisomy 21, in both high-risk and general populations [3] [4] [5] .
The accuracy of the test depends on the proportion of the total cfDNA that contains fetal genetic material (i.e. the fetal fraction), with it being higher when the fetal fraction is high and lower when the fetal fraction is low 6 . While not all laboratories offering cfDNA testing measure fetal fraction, some companies that do will not provide a result if the fetal fraction is below 4%. Previous studies show that fetal fraction increases with advancing gestational age, decreases in pregnancies conceived by in-vitro fertilization (IVF) and in women with increased body mass index (BMI), and can vary according to ethnic origin [7] [8] [9] .
Since cell-free 'fetal' DNA originates from the developing placenta 10 , studies have suggested that the release of cell-free fetal DNA would be related to the size of the placenta and to the rate of trophoblastic apoptosis 11 . Therefore, cfDNA and fetal fraction measurements could potentially be used as a screening test for placental disorders such as pre-eclampsia (PE) and fetal growth restriction (FGR).
There has been an increasing interest in screening for PE in the first trimester, particularly since the publication of recent meta-analyses 12, 13 and a large randomized controlled trial showing that aspirin intake initiated before 16 weeks' gestation is effective in reducing the prevalence of preterm cases of PE 14 . Although various studies show an increase in both fetal and total cfDNA in the maternal circulation in women diagnosed with PE [15] [16] [17] [18] [19] , little is known regarding fetal fraction in these cases and whether its measurement could be used as a marker of placental dysfunction in asymptomatic women 20 . Since recent studies have shown a positive linear correlation between fetal fraction and other biochemical markers of placental function 21 , women at increased risk for placental disorders would be more likely to have reduced fetal fraction on cfDNA testing 22 or to receive a failed result. The literature is scarce on the possible association of fetal fraction with predictive markers and risk for developing PE in the general population.
The aim of this study was to evaluate if fetal fraction on cfDNA testing is associated with first-trimester biophysical and biochemical markers for PE, as well as to investigate the possible association of low fetal fraction with increased risks for PE and FGR.
SUBJECTS AND METHODS

Study population
This was a retrospective cohort study including all women with a singleton pregnancy who had first-trimester risk calculation for PE and FGR between 11 + 0 and 13 + 6 weeks' gestation who also had cfDNA analysis as a primary or secondary screening test for fetal chromosomal abnormalities, at any gestational age, at two private fetal medicine clinics in Sydney and Melbourne, Australia. Only cases between March 2013 and May 2017 with fetal fraction reported were included. Multiple pregnancies and cases with uninformative results were excluded from the analysis.
Procedure and data collection
Each participating ultrasound practice has a wellestablished program of first-trimester combined screening for fetal chromosomal abnormalities, comprising fetal structural assessment and measurements of nuchal translucency and biomarkers (free β-human chorionic gonadotropin (β-hCG), pregnancy-associated plasma protein A (PAPP-A) and placental growth factor (PlGF)). All patients who opted to have this test as first-tier screening were also offered risk calculation for PE at the same time.
Women who opted to have cfDNA testing as the primary screening method before 11 weeks' gestation had an ultrasound examination prior to blood sampling in order to confirm pregnancy viability and exclude multiple pregnancy, and were advised to return for fetal structural assessment between 11 + 0 and 13 + 6 weeks' gestation. In all cases, gestational age was calculated based on fetal crown-rump length (CRL) at 11 + 0 to 13 + 6 weeks' gestation.
Maternal demographic characteristics were recorded, as well as medical, obstetric and family history. Mean arterial pressure (MAP) was calculated following a previously published technique 23 , using the average of two measurements in each arm. Both left and right uterine artery pulsatility indices were measured using a standardized technique 24 and the mean value was recorded. The individual risks for FGR requiring delivery before 37 weeks of gestation and for PE requiring delivery before 34 and 37 weeks of gestation were calculated using The Fetal Medicine Foundation (FMF) algorithm 25 , combining maternal factors, MAP and uterine artery pulsatility index (UtA-PI) for all cases and also PAPP-A and PlGF when biochemistry results were available. All markers were expressed as multiples of the median (MoM) after adjustment for gestational age and maternal characteristics.
Blood samples for cfDNA testing were analyzed in the USA (Harmony ® , Roche/Ariosa Diagnostics Inc., San Jose, CA, USA) or Australia (Douglass Hanly Moir, Queensland, Australia), as described previously [26] [27] [28] . In samples with a fetal fraction < 4%, the laboratory did not report fetal fraction or generate a cfDNA risk assessment.
As this was a clinical audit of a validated screening program that did not identify patients directly and did not seek pregnancy outcome information, patient consent was not required. The study involved de-identified data for analysis and quality assurance purposes, and therefore ethical clearance was not required, as per the National Health and Medical Research Council's 2014 Ethical Considerations in Quality Assurance and Evaluation Activities 29 .
Statistical analysis
Baseline characteristics of the population were expressed as absolute value and percentage for categorical variables and median and interquartile range (IQR) for continuous variables. The distribution of fetal fraction was made Gaussian using logarithmic transformation, and linear regression analysis was performed in order to identify which of the maternal characteristics affect log 10 fetal fraction values. The results were then adjusted for gestational age and maternal characteristics and expressed as MoM (log 10 fetal fraction MoM).
First-trimester markers for pre-eclampsia (MAP, UtA-PI, PAPP-A and PlGF) were also expressed as MoM and logarithmically transformed. To compensate for the potential effect of missing values for MAP, UtA-PI and risks (missing completely at random, < 5%), linear regression-based sensitivity analysis was conducted using a multiple imputation strategy (M = 10) and pooled results were used.
The associations of fetal fraction with PE markers and risks for PE and FGR were evaluated using Pearson correlation analysis and univariable and multivariable truncated linear regression analysis (as fetal fraction values < 4% were not included in the dataset). These associations were represented in scatterplot charts with lines of best fit from truncated regression and Lowess mean estimation lines.
Separate analyses were performed for the group with and that without biochemistry in order to assess possible differences between these two groups that could introduce bias. Statistical analysis was performed using the software Stata version 14.1 (StataCorp LP, College Station, TX, USA).
RESULTS
A total of 4317 singleton pregnancies with first-trimester screening for PE and cfDNA results with fetal fraction reported were included. Of those, 2252 (52.2%) had Data are presented in median (IQR), n (%) or n/N (%). APS, antiphospholipid syndrome; FGR, fetal growth restriction; GA, gestational age; IVF, in-vitro fertilization; PE, pre-eclampsia; SLE, systemic lupus erythematosus. Table 2 Uni-and multivariable truncated regression analyses for association between first-trimester markers for pre-eclampsia and log 10 fetal fraction multiples of the median (MoM) in singleton pregnancy screening for PE with all four markers included, and 2065 (47.8%) had PE risk calculation without biochemical markers. Baseline characteristics of the population are shown in Table 1 . Gestational age had a significant positive association with log 10 fetal fraction. Of the maternal factors, conception by IVF, increased maternal age, increased BMI, chronic hypertension, type 1 or type 2 diabetes mellitus and South Asian ethnicity were associated significantly with reduced log 10 fetal fraction. Being parous without history of PE or FGR was associated significantly with higher log 10 fetal fraction values.
On univariable analysis, both log 10 MAP MoM and log 10 UtA-PI MoM showed a significant inverse association with log 10 fetal fraction MoM (P < 0.001 for both; Table 2 and Figure 1 ), and this association was maintained on multivariable analysis including only these two markers. Log 10 PAPP-A MoM and log 10 PlGF MoM had a significant positive association with log 10 fetal fraction MoM (P < 0.001 for both; Table 2 and Figure 2 ). Consequently, there was also a significant negative correlation between log 10 fetal fraction MoM and the log 10 inverse risks for PE before 34 weeks, PE before 37 weeks and FGR before 37 weeks (all P < 0.001; Figure 3 ). Using a risk cut-off of 1 in 100 for PE before 37 weeks' gestation, median fetal fraction in the high-risk group was 10.4% (IQR 7.8-13.2%), compared with 11.8% (IQR 9.2-14.8%) in the low-risk group (P < 0.001).
On multivariable analysis including only cases in which all four markers were measured, the associations of log 10 UtA-PI MoM and log 10 PlGF MoM with log 10 fetal fraction MoM did not remain independently significant after addition of log 10 PAPP-A MoM to the model (Table 2) .
There were no significant differences in baseline characteristics, and the results of the linear regression were similar in the group with and that without biochemistry, suggesting that the coefficients would be similar if all the included cases had results for PAPP-A and PlGF.
DISCUSSION
Main findings
The findings that MAP and UtA-PI are associated negatively with fetal fraction and that PAPP-A and PlGF are associated positively with fetal fraction reinforce the hypothesis that lower fetal fraction may be a consequence of smaller placental mass and even an early sign of placental dysfunction. This study, to the best of our knowledge, is the first to analyze a possible correlation between fetal fraction and biophysical markers for PE. The results suggest that women at increased risk for PE and FGR tend to have lower fetal fraction, which is in keeping with findings reported previously by Norton et al. in a large study comparing women who developed PE with those who did not 22 . Previous studies have reported increased quantities of both total and fetal cfDNA in the circulation of women diagnosed with PE [16] [17] [18] [19] , and marked increases in those with severe PE 30 . These findings have been attributed to accelerated apoptosis of trophoblastic cells as a result of placental ischemia, inflammatory nature of the vascular and end-organ damage, and reduced clearance of cfDNA from the maternal circulation in cases of placental dysfunction 31 . The apparently discrepant results (lower fetal fraction as opposed to increase in absolute quantities of fetal cfDNA) may be due to a less-pronounced increase in fetal compared with maternal cfDNA, with a consequent reduction in fetal fraction.
Few studies have evaluated the potential use of cfDNA measurements as a screening test for PE in asymptomatic women. Recent systematic reviews were unable to draw definitive conclusions on its potential predictive value 17, 32 . In a case-control study, Rolnik et al. demonstrated that, in patients with early-onset PE, the total and fetal cfDNA are increased and the fetal fraction is reduced, but such associations were not seen after adjustment for maternal characteristics that affect these measurements 33 .
Scott et al. have also demonstrated a significant positive association of biochemical markers and fetal fraction on cfDNA testing 21 . In our analysis, however, the associations of PlGF and UtA-PI with fetal fraction did not remain significant on multivariable linear regression analysis when all markers were included in the model. This is possibly due to the strong association of PAPP-A with fetal fraction and the fact that there is some degree of overlap between different first-trimester markers, with lower values of UtA-PI and higher values of PlGF associated with higher PAPP-A results.
Clinical implications and study limitations
The findings of this study support the hypothesis that low fetal fraction is associated with a higher risk of developing PE or FGR, as there is a clear association between fetal fraction and first-trimester markers, and consequently with the individual risk for development of these conditions. Cases with fetal fraction < 4% were not included in this study, but it would be reasonable to expect a higher chance of uninformative results due to low fetal fraction among patients at high risk for PE and FGR. Accordingly, Chan et al. reported a significantly higher rate of pre-eclampsia among patients who had an uninformative result due to low fetal fraction compared with in the general obstetric population 34 .
It is unclear whether the addition of fetal fraction to a multi-marker screening test would increase the accuracy of the test, as the effect of this parameter in the risk calculation may not be clinically significant and independent once other markers that show an association with fetal fraction are also included in the predictive model. Further research on this topic is needed to investigate this hypothesis.
Moreover, although our results suggest that this would be the case, it is crucial to identify if patients who indeed developed preterm PE or FGR have lower fetal fraction when compared with that in uncomplicated pregnancies. If so, fetal fraction could potentially enhance first-trimester screening for PE, particularly in cases in which placental biochemistry was not performed. The fact that pregnancy outcomes were not collected is one of the main limitations of this study, and this is now being addressed in a large pregnancy outcome study from both units.
Another limitation of this study was the fact that half of the analyzed cohort did not have results for PAPP-A and PlGF. However, the number of pregnancies analyzed was large, the number of cases with biochemistry included was also considerable, and a separate analysis including pregnancies with and those without biochemistry results showed no significant differences between the groups, which is reassuring.
Conclusions
Low fetal fraction on cfDNA testing may be a marker of poor placental development and placental dysfunction, as there is a significant correlation with first-trimester markers for PE and risks for PE and FGR. Nonetheless, the possible benefit of using fetal fraction to improve current predictive models is unclear and merits further research.
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